Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Puma Biotechnology Inc. (PBYI)

13.96   0.03 (0.22%) 02-20 16:00
Open: 14.09 Pre. Close: 13.93
High: 14.95 Low: 13.77
Volume: 2,766,264 Market Cap: 547M
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 14.972 - 15.033 15.033 - 15.095
Low: 13.631 - 13.69 13.69 - 13.75
Close: 13.863 - 13.966 13.966 - 14.071

Technical analysis

as of: 2020-02-20 4:42:42 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 17.52     One year: 20.46
Support: Support1: 10.52    Support2: 7.75
Resistance: Resistance1: 15.00    Resistance2: 17.52
Pivot: 11.89
Moving Average: MA(5): 13.15     MA(20): 11.01
MA(100): 8.92     MA(250): 15.81
MACD: MACD(12,26): 1.26     Signal(9): 1.02
Stochastic oscillator: %K(14,3): 82.31     %D(3): 74.61
RSI: RSI(14): 68.74
52-week: High: 43.90  Low: 6.26  Change(%): -47.7
Average Vol(K): 3-Month: 217492  10-Days: 188955

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
PBYI has closed below upper band by 26.0%. Bollinger Bands are 149.7% wider than normal. The large width of the bands suggest high volatility as compared to PBYI's normal range. The bands have been in this wide range for 10 bars. This is a sign that the current trend might continue.

Headline News

2020-02-20
Puma Biotechnology EPS beats by $0.27, beats on revenue
Puma Biotechnology (NASDAQ:PBYI): Q4 Non-GAAP EPS of $0.01 beats by $0.27; GAAP EPS of -$0.29 beats by $0.19. Revenue of $62.9M (-11.5% Y/Y) beats by $2.94

2020-02-20
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Feb. 20, 2020, Puma Biotechnology released its financial results for the fourth quarter and full year ended Dec. 31, 2019.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 39.20
Shares Float (M) 30.12
% Held by Insiders 11.70
% Held by Institutions 83.29
Shares Short (K) 6960
Shares Short P. Month (K)

Stock Financials

EPS -2.470
Book Value (p.s.) 0.440
PEG Ratio -0.03
Profit Margin -33.91
Operating Margin -17.45
Return on Assets (ttm) -13.2
Return on Equity (ttm) -301.4
Qtrly Rev. Growth -10.0
Gross Profit (p.s.) 5.520
Sales Per Share
EBITDA (p.s.) -1.037
Qtrly Earnings Growth
Operating Cash Flow (M) 27.86
Levered Free Cash Flow (M) 65.93

Stock Valuations

P/E -5.65
P/E Growth Ratio
P/BV 31.73
P/S 1.92
P/CF 19.64

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.